海思科(002653.SZ)擬定增募資不超8.21億元 用於長效口服降血糖新藥HSK-7653的中國III期臨牀研究及上市註冊項目等
格隆匯 9 月 14日丨海思科(002653.SZ)披露2020年度非公開發行A股股票預案,此次非公開發行股票預計募集資金總額不超過約8.21億元(含此數),扣除發行費用後的募集資金淨額後的具體用途如下:3.9512億元用於長效口服降血糖新藥HSK-7653的中國III期臨牀研究及上市註冊項目;約1.24億元用於新型周圍神經痛治療藥物HSK-16149膠囊的中國II/III期臨牀研究及上市註冊項目;5655.05萬元用於鹽酸乙酰左卡尼汀片的中國上市後再評價項目;2.45億元用於補充流動資金及償還銀行貸款。
此次非公開發行A股股票數量不超過4000萬股(含此數),按目前公司總股本測算,佔公司發行前總股本的比例不超過3.72%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.